Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Q1 2025 Management View CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and ...

Altimmune's stock, which was added to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, ...

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Dec 5 (Reuters) - Weight-loss drug developer Altimmune (ALT.O), opens new tab is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its ...

Immunotherapies company Altimmune Inc. plans to go public by merging with biodefense specialist PharmAthene Inc. in a deal that gives Altimmune backers control over the combined business.

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...

Altimmune Inc. advanced stock charts by Barron's. View ALT historical stock data and compare to other stocks, and exchanges.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ...